A chemo-centric view of human health and disease by Duran Frigola, Miquel et al.
  1 
 
A chemo-centric view of human health and 
disease 
 
Miquel Duran-Frigolaa, David Rossellb,c and Patrick Aloya,d,* 
 
a. Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in 
Biomedicine (IRB) Barcelona, c/ Baldiri Reixac 10-12, 08028 Barcelona, Spain 
b. Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB) 
Barcelona, Spain 
c. Department of Statistics, University of Warwick, Coventry, United Kingdom 
d. Institució Catalana de Recerca i Estudis Avançats (ICREA), Pg. Lluís Companys 23, 
08010 Barcelona, Spain 
 
* Corresponding author: Patrick Aloy. Institute for Research in Biomedicine (IRB) 
Barcelona, c/ Baldiri Reixac 10-12, 08028 Barcelona, Spain. Tel: +34 934039690; Email: 
patrick.aloy@irbbarcelona.org 
 
Keywords: Fragment Mining, Disease Models, Disease Networks 
 
  
  2 
Abstract 
Efforts to compile the phenotypic effects of drugs and environmental chemicals offer the 
opportunity to adopt a chemo-centric view of human health. In this manuscript we consider 
thousands of chemicals and analyze their relationship with adverse and therapeutic 
responses. Our study includes molecules related to the etiology of 934 health threatening 
conditions and used to treat 835 diseases. We first identify chemical moieties that could be 
independently associated with each phenotypic effect, balancing interpretation and 
prediction efficiency to maximize the biological relevance of the reported molecular 
fragments. Using these fragments, we build accurate predictors for approximately 400 
clinical phenotypes, finding many privileged and liable structures. Finally, we connect two 
diseases if they relate to a similar chemistry. The resulting networks of human conditions are 
able to predict disease comorbidities, as well as identifying potential drug side effects and 
opportunities for drug repositioning, and show a remarkable coincidence with clinical 
observations.  
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Humans, in their daily lives, are exposed to a great variety of chemicals, including drugs and 
environmental hazards. Therapeutic and adverse effects of these chemicals result from a 
complex interplay with the human body. It is now recognized that, in most cases, a 
reductionist viewpoint of such interplay is far from reality. Cumulative evidence shows that 
even the most thoughtfully specific drugs elicit promiscuous interaction profiles1 and, 
accordingly, many adverse chemical events lack a compelling molecular explanation2. The 
emerging opinion is that systems biology strategies —that integrate several layers of detail 
and complexity— will be necessary to zoom out from a reductionist to a more holistic picture 
of pharmacology and toxicology3. 
As human biology continues to reveal itself more and more intricate, it is suggestive to 
realize that much information about the behavior of a chemical inside our bodies is encoded 
within a small molecule, with few bonds and atoms. Decoding correlations between the 
structure of a compound and its activity in biological systems has been a prolific research 
area, and the major goal of earliest pharmacologists4. Unfortunately, such a compound-
centered view of phenotypes is blind to molecular mechanisms, lacking theoretical support 
and, therefore, requiring a considerable amount of bioactivity data. In particular, for humans, 
experiments to obtain this information cannot be conceived, and the bulk of chemical activity 
assays is placed several translational steps backward (i.e. at the level of single receptor 
binding), with the consequent reduction of the system complexity. 
Recent advances in text-mining techniques and subsequent curation efforts are committed 
to compiling direct human response data from the knowledge accumulated through the 
years5,6. Here, we benefit from this enterprise to revisit the classical structure-activity 
relationship notion, this time for a vast and diverse list of human diseases. Concretely, we 
first delve into chemical structures to identify fragments that are associated with adverse or 
therapeutic responses. Then, we propose disease models based on these fragments, and 
assess their predictive efficiency. Finally, we use such models to relate diseases, providing a 
chemical map of human phenotypes. 
Results and Discussion 
Several resources exist that contain information on the interaction of small molecules with 
our health. Most notably, the Comparative Toxicogenomics Database (CTD)5 is mainly 
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focused on environmental chemicals, and reports curated relationships with a 
comprehensive list of diseases. Moreover, it classifies disease annotations as 
‘Marker/Mechanism’ (M) or ‘Therapeutic’ (T). M refers to a chemical that correlates with the 
disease (i.e. a marker) or may act in its etiology (i.e. a toxin), while T indicates that the 
chemical has a known or a potential therapeutic role in the condition (i.e. a drug). By 
analogy, hereafter we refer to adverse and therapeutic disease outcomes simply as M and T 
diseases, respectively. 
Research worldwide is conducted at different levels of detail and, accordingly, CTD curators 
index publications with a hierarchical organization7. For instance, while some reports simply 
congregate ‘Skin diseases’, others are centered on ‘Dermatomyositis’, and even some are 
focused on a subtype of this condition called ‘Amyopathic dermatomyositis’. Broad disease 
terms are obviously associated with more molecules (direct annotations plus those regarding 
child terms); however, they can involve diverse or more intricate mechanisms. As a 
consequence, extracting molecular rules for imprecise phenotypes may be as challenging as 
for very specific cases, where data are scarce. We have explored the disease hierarchy with 
the intuition that, in between general and specific disease concepts, there will be enough 
information to learn structure-activity relationships. 
In total, 934 M and 835 T diseases could be analyzed after considering 8,881 molecules 
(Table 1). These diseases span the medical hierarchy endpoints, and thus are 
representative of the variety of known human conditions. 
Chemical Fragment Mining 
As a first step in the chemo-centric disease analysis, we sought to list chemical moieties that 
could be independently associated with the phenotype. Support for this idea is provided by 
examples of chemical scaffolds showing a strong correlation with bioactivity profiles8,9. 
Given, for example, an M set of molecules (i.e. biomarkers and toxins of a particular 
disease), we performed an exhaustive molecular fragmentation and, among the resulting 
fragmentsa, we kept those that were over-represented with respect to compounds unrelated 
to the disease. We considered non-redundant sets of molecules to minimize annotation 
biases, and designed the statistical analysis so that the final selection of fragments was 
simplified in terms of substructural dependencies, without detrimenting posterior predictive 
models (see Materials and Methods). Exactly the same procedure was applied to 
therapeutic annotations, examining T molecules instead. 
                                                
a In this work, the terms ‘fragment’, ‘moiety’, ‘chemotype’ and ‘scaffold’ are used interchangeably. 
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The median molecule broke into 5 fragments, ranging from a single piece up to 200. A total 
of 98,077 moieties were considered. After the significance analysis, both for M and T sets, 
we obtained around 200 over-represented fragments per disease, and for each fragment we 
found 4 associated diseases. Due to initial permissive statistical requirements, this 
constituted a Low Confidence (LC) set of ~5·104 fragment—disease associations that was 
ideal for later achieving predictive power. When we controlled for the False Discovery Rate 
(FDR) below 1% and applied additional constraints (Materials and Methods), we obtained a 
subset of 7,411 High Confidence (HC) fragment—disease pairs (Table S1). These 
fragments are well represented in the known bioactive chemical space (Figure S1), and 
include both expected and novel moieties, emerging from diverse sets of molecules (Figure 
S2). Within HC pairs, a fragment was related to a median of 2 M or T diseases, and a 
disease was linked to 6 fragments (Figure 1A). At least one HC fragment could be found for 
41% and 50% of M and T diseases, respectively (Table 1), providing a chemo-centric 
molecular description of phenotypes that is interpretable for the medicinal chemist, a 
property that has been recently vindicated in chemoinformatics10. 
Over-represented Fragments in the Chemical Space 
Identified fragments exhibit a varied chemical repertoire (Figure 1B). HC moieties have a 
median size of 17 atoms, including 1 ring and 4 heteroatoms. Interestingly, 32% of the 
fragments follow the ‘Rule of Three’ (Ro3) (molecular weight (MW) < 300, number of 
hydrogen bond donors (HBD) ≤ 3, number of hydrogen acceptors (HBA) ≤ 3 and logP ≤ 3). 
Backwards studies found that fragments that accomplish these rules are good starting points 
to meet the Lipinski condition11, or ‘Rule of Five’, that concerns bioavailability of oral drugs 
(i.e. MW < 500, HBD ≤ 5, HBA ≤ 5 and logP ≤ 5). 
Activity-related fragments offer a simple way to compose customized chemical spaces. In 
Tables S1 and S2, they are given together with associated diseases, enabling the design of 
tailored chemical libraries. In general, while our collection covers a broad and representative 
spectrum of chemical features, it also reflects the diversity of CTD and most 
chemogenomics repositories12 (Figure 1A, middle), which contain only a small number of 
well-represented scaffolds, and a large proportion of singular moieties. The balance between 
variety of fragments and coverage will depend on the needs. Similar to the case of kinase-
focused libraries13, we might want to achieve a thorough coverage of a narrow 
pharmacological space to address e.g. ‘Anterograde Amnesia’, where only 2 HC fragments 
represent 55% of the beneficial molecules. Sparse libraries would be preferable in cases like 
‘Chronic Obstructive Pulmonary Disease’, where as many as 34 HC fragments can be 
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extracted from the corresponding 27 medicines, spanning 74% of the active space and 
requiring a higher diversity. 
Accounting for this diversity is crucial in order to move away from chemical clichés14. The 
structural variety of known drugs15 and, in general, of registered compounds is very low —
the more frequently a scaffold has been used, the more likely it will be used again16. 
However, we have seen that our reported fragments not always emerge from well-studied 
moieties, yielding valuable novel chemotypes (Figure S2). Recently, it has been suggested 
that a large part of fragment space is indeed synthetically accessible, which also calls for a 
more exploratory chemistry17. If orphan regions of chemical space are to be populated, we 
propose that our findings could aid the charting of its biologically relevant, primordial regions.  
Existence of Liable and Privileged Structures 
When analyzing over-represented structures, the immediate question is whether fragments 
exist that are mostly associated with adverse events, while others are usually present in 
therapeutic molecules (Figure 2A). The former would correspond to problematic structures 
that should be avoided in, for instance, medicinal chemistry endeavors18. On the contrary, 
the latter are desired, privileged chemotypes of potential profit in the design of libraries for 
forward pharmacology practices like cell-based phenotypic screening19. 
As expected, it was slightly easier to detect privileged than liable structures (384 vs 367 
liable HC fragments, respectively, over a total of 45,607 T and 72,804 M chemical—disease 
pairs considered (Table 1)). The medicinally relevant space is influenced by size constraints 
and ease of synthesis20, and pharmaceutical research is often incremental. Liable 
fragments, which also occur in drugs and environmental chemicals, may have been 
abandoned or remained unperceived, and thus are less well represented (Wilcoxon’s test 
(Wt) p-value < 2.2·10-16) (Figure S3). As a consequence, the LC liable fragment occurs in a 
higher proportion of M compound—disease pairs than the LC privileged fragment in T pairs 
(Wt p-value 8.0·10-10), implying that it might be important across a range of phenotypes, 
although we can only capture the association with weak statistical signal. On the other hand, 
as expected, the trend is inverted for HC fragments (Wt p-value 1.4·10-6), since only a 
thorough exploration of chemical space allows for extraction of strong structure-activity 
relationships. 
Of particular interest are those privileged fragments that have not been successfully used in 
drug development yet. Out of the 367 fragments that could be considered as privileged 
(>80% T both in HC and LC sets), 40% were not present in any approved or experimental 
drug reported in the DrugBank21 (note that CTD scope goes beyond drug molecules: 45% of 
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the compounds with T annotations were not found in DrugBank above a similarity cutoff of 
0.8). In Figure 2B, for example, fragment 1 constitutes a fraction of the ergoline tetracycle. 
Mesulergine is a psychoactive compound of the ergoline class with a halted development 
due to adverse histological abnormalities in rats22. We speculate that 1, that is present in 6 
other molecules in CTD, could be kept and used to derive safer compounds outside the 
ergoline family. Fragment 2 is a propanolamine that we found useful to treat ‘Cardiac 
Arrythmias’ and could be further evolved into Alprenolol alternatives, a close analog in the 
market. Finally, 3 is the scaffold of Dexelvucitabine, a failed anti-HIV and anti-HBV agent 
that, while singular in structure, displays features similar to other desirable chemotypes, and 
is found over-represented in as many as 8 therapeutic indications —safer derivatives of 
Dexelvucitabine could be of potential interest. 
Another group of interesting moieties, at least in retrospective, corresponds to those that are 
frequently included in drug molecules despite being mostly associated with adverse events. 
We recognize that, in general, drugs (usually prescribed for few indications) will indeed elicit 
many adverse reactions. However, in CTD the M:T annotation rate is quite balanced (less 
than 2:1), making >80% M a meaningful definition of a liable fragment. In the right panel of 
Figure 2B, structure 4 accounts for the prototypical hydrochlorothiazide, a class that includes 
methylclothiazide and cyclothiazide. Despite its popularity, we found a large number of 
adverse events associated to this class, ranging from ‘Hypokalemia’ to ‘Arthritis’. As done 
elsewhere23, 4 could undergo a scaffold-hopping exercise to find better analogs. Fragment 
5, present inside 13 medicines like Sufentanil, constituted a liable HC fragment for 5 
conditions, including ‘Sinus Arrythmia’ and ‘Muscle Hypertonia’. Similarly, 6 is part of several 
bronchodilator agents and resembles the ancestor Norepinephrine drug. We found 8 HC 
associations of 6 with inconvenient events such as ‘Tachycardia’ and ‘Hypertension’, 
suggesting that further generations of Norepinephrine successors are likely to remain 
unsafe. 
Predictive Models 
Although valuable, identifying the presence of a characteristic fragment in a molecule is 
usually not enough to accurately infer an association with a disease24,25. Very often, a 
combination or mutual exclusion of several moieties will determine the outcome. In general, 
predictive power and interpretability of structure-activity models are two different objectives 
that are difficult to achieve simultaneously. On this matter, a good tradeoff is offered by LC 
fragments, which are more frequent among disease-related molecules, and thus are 
promising variables for starting machine learning24.  
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Given its reduced cost, fragment-based learning can be applied at virtually every step of the 
drug discovery pipeline, and offers a means to join chemoinformatics with expert opinion26. 
Its performance will largely depend on the specificity of the underlying biology, and the 
proper, delimited representation of the active chemical space. As a result, while detecting 
over-represented fragments gets easier for highly annotated, broad disease terms, 
predictive capability does not follow the same trend (Figure S4). 
We built a fragment-based chemical classifier for each of the 934 M and 835 T diseases 
(Figure 3) using Random Forests (RFs). RFs allow detecting interactions between 
fragments, e.g. when the combination of two fragments has a therapeutic effect but each 
individual fragment does not. Table 1 provides a general view of the results. It shows, for 
instance, that point prediction performance metrics sensible to data imbalance (namely the 
positive predictive value and the F1-score) take values close to zero. This is an expected 
observation given the pronounced imbalance of positive:unknown sampling (a median of 
30:4,250). Also, note that sensitivity could be increased at the expense of the high 
specificity, and that the decision cutoff could slide at will so that e.g. G-mean is optimized 
(see Materials and Methods). The area under the ROC curve (AUC) measures the 
compromise between sensitivity and specificity at all possible cutoffs, and it is widely used to 
assess the performance of predictive models. Overall, 184 M and 216 T disease models 
exhibited a cross-validated AUC above 0.7. The successful models did not display a distinct 
chemistry (Figure S5), and covered 13% and 7% of the full medical hierarchy endpoints, 
respectively. Together, both results evidence our scarce knowledge of the relevant chemical 
space, and the difficulty to assess a priori if a region of it has been sufficiently exploited. 
Therapeutic Effects are Better Predicted than Adverse Events 
When analyzing accurate, plausible classifiers (AUC > 0.7), the first observation is that 
therapeutic outcomes are better modeled than adverse events, i.e. there is a larger 
proportion of T cases with AUC > 0.7 (Fisher’s test (Ft) p-value 0.001, and Wt p-value 3·10-8 
for whole distributions) (Figure 3). Again, this arises from the fact that the therapeutic space 
is composed of incremental discoveries (Figure S3), and emphasizes the difficulty of the 
predictive toxicology task. 
ROC curves on the right of Figure 3 correspond to satisfactory models of T diseases. 
‘Osteomyelitis’, that refers to bone infections, is treated with antibiotics of well-used families 
(quinolones, cephalosporins, penicillins, etc.). Thus, it is easy to infer whether a molecule 
will be suitable for addressing such condition. A similar chemistry has been learned for 
‘Pseudomonas Infections’, for instance. Analogous conclusions can be drawn for ‘Paranoid 
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Schizophrenia’, where e.g. benzodiazepines and phenothiazines are annotated, and for 
‘Supraventricular Tachycardia’, a cardiovascular complication of which the aforementioned 
propanolamines are prominent examples. 
Other chemicals, rather than treating, may trigger cardiovascular events. In fact, these are 
commonly alerted drug side effects. Pergolide, for instance, was withdrawn from the market 
due to heart issues —we predicted its association with ‘Aortic Valve Insufficiencies’ (this 
annotation was not available from CTD). A plausible model was also obtained for 
‘Mesenteric Valve Insufficiencies’ (left ROC curves in Figure 3). In general, for heart events, 
even when the underlying biology remains intricate27, there is a chemical signal that can aid 
prevention. In Figure 3, we also display the cross-validation of the ‘Uterine Hemorrhage’ 
model, and, regarding the same organ, that of ‘Endometrial Neoplasms’. 
Not All Types of Diseases are Equally Predictable 
Following the last example above, we find support for the intuition that traveling the disease 
hierarchy from specific to broad terms can help to find informative chemical sets. 
Accordingly, while ‘Neoplasms’ are poorly understood as a whole (AUC 0.66), we obtained a 
number of accurate models for certain organs and types (Figure 4). In particular, we could 
solve many M cancer cases, while few successful T models existed. This illustrates that we 
know more of the chemistry of carcinogens and cancer markers than of the chemistry that is 
needed to cure it. A similar conclusion could be drawn for ‘Male’ and ‘Female Urogenital 
Disorders’. On the contrary, we could provide several plausible classifiers for the treatment 
of ‘Mental Disorders’, meaning that the chemical space that addresses such conditions has 
been well exploited. Similarly, we have deep knowledge on treating ‘Bacterial Infections and 
Mycoses’ while, as expected, there is little chemistry that may facilitate them (the only 
example we found was ‘Candidiasis’, where most relevant structures corresponded to 
steroidal frameworks like glucocorticoids28). The rest of disease classes shared, in general, 
a balance between M and T plausible models. Remarkably, some disease classes were 
poorly modeled. We attempted, for instance, 41 M ‘Eye Diseases’, of which as few as 3 
yielded a satisfactory classifier. Similarly, we only obtained a good predictor for 4 of the 28 T 
‘Endocrine System Disorders’ (Figure S6). 
Indeed, for a majority of diseases we lack an accurate model. We believe, however, that 
there is room for improving chemical classifiers based on literature mining. One important 
hindrance in training these classifiers is the absence of truly negative data (chemical—
disease pairs that have been verified not to interact, as opposed to not having been 
observed so far). The so-called ‘positive-unlabeled learning’ tackles this issue and is now 
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being implemented in biomedicine29. However, in our hands, such methodologies30,31 did not 
improve predictive power, most likely due to the sparseness and reduced size of the set of 
unknowns (Figure S7), an issue that, most likely, will be solved as disease—chemical 
annotations continue to increase32. Also, including physicochemical properties of 
compounds could be of enormous interest, particularly in the case of adverse events, where 
mechanisms of action may not be target-driven. Accordingly, the identification of 
toxicophores is usually thought of in metabolic and reactivity terms18, since toxic effects can 
result from polar or nonpolar processes, uncoupling of oxidative phosphorylation, thiol-
alkylation, etc. In this regard, reactivity prediction methods should be appropriate33, 
particularly for nonspecific complications like tissue necrosis, carcinogenicity, or immune-
mediated toxicities. Recently, a combination of structure and reactivity analysis was applied 
to select groups that shared structure and electronic state34, and it was recommended that 
compounds undergo a structural clustering before the reactivity assessment, suggesting that 
our results could be readily complemented with reactivity profiles. 
Disease Networks Based on Underlying Chemistry 
In this study, we have analyzed each disease separately. However, results should be 
integrated to provide a general view. For this purpose, network representations are a 
prominent systems biology tool because they integrate relationships between different 
entities, facilitating contextualization and providing a general view35,36. In particular, disease 
networks help to assimilate the diversity of human conditions. In a seminal work, Goh et al. 
proposed that two diseases could be related if they share a genetic origin37. The resulting 
disease network was able to unveil biological modules and therefore offered a means to link 
the molecular and the organism levels. 
Instead of connecting two diseases when the same genes participate in their etiology, we 
link them if they relate to a similar chemistry, i.e. when the molecules associated with the 
one are comparable to those associated with the other. The resulting chemo-centric map of 
human conditions is of singular interest for drug development, since it is focused on 
intervention, i.e. on disease relationships that are directly based on effector compounds. 
 
 
The Disease Comorbidity Network 
When we relate M disease models, the corresponding network is a comorbidity map, where 
two conditions are connected if the toxins and markers of the one are similar to those of the 
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other, implying that the two diseases could occur simultaneously. In practice, we screened 
all M molecule sets annotated to the 934 diseases against the 184 successful M models, 
and we related two diseases if the AUC of the cross-classification was higher than 0.7. This 
yielded a network of 12,610 edges (Tables 2 and S3). Interestingly, such a chemo-centric 
comorbidity map captured disease co-occurrences detected in the history of more than 30 
million patients38: a medical semantics mapping found that a large number of our disease 
associations have indeed been observed in the clinics (9,788 matches, the corresponding 
contingency table yielded a Ft p-value of 4.5·10-28), providing an excellent independent 
validation of our findings (see Materials and Methods). For instance, we predicted that 
molecules associated with ‘Aortic Valve Insufficiency’ are likely related to ‘Neuroleptic 
Malignant Syndrome’ (AUC 0.88). In turn, the ‘Aortic Valve Insufficiency’ model up-ranked 
‘Elimination Disorders’ molecules (AUC 0.82) (Figure 5). In patients, not necessarily due to 
exposure to chemicals, these relationships have been observed with relative risks of 56.7 
and 29.5, respectively38. Overall, together with e.g. studies of metabolic pathways39, our 
results show that a chemical viewpoint is useful to account for the underlying molecular 
connection of human conditions. 
The Drug Repositioning Network 
Analogously, we may relate diseases based on T records and obtain a network that links two 
conditions when medicines for the first could also serve in the second. This so-called ‘drug 
repositioning network’ is appealing given the time and financial burdens of the drug 
discovery process. Currently, a number of computational approaches are taken in this 
direction40, and even the simplest methods41 are proposing remarkable opportunities. After 
screening the 835 T compound-disease pairs against the 216 good T models, we obtained a 
network of 14,590 edges (Tables 2 and S4). Some diseases like ‘Hypertension’ had a high 
in-degree (in this case, 235), meaning that they could be the repurposing opportunity of 
many indications, reflecting the clinical complexity of this physiological phenomenon 
associated with cardiovascular, endocrine and nervous system components. On the other 
hand, ‘Urethral Diseases’ displayed an out-degree of 137, i.e. its 11 medicines could have 
several other uses. When compared to a network drawn from approved indications of 
drugs42, we observed a significant overlap (10,731 common edges, Ft p-value 3.4·10-13), 
reinforcing the validity of our results. This network based on approved drugs represents the 
polypharmacy of medicines, and links two diseases if they are treated by a significant 
number of common drugs (see Materials and Methods). Even after a conservative semantic 
mapping, 3,859 of our repositioning opportunities were not found in such network, implying 
that they remain largely unexplored. Among these, we propose the use of ‘Rhinitis’ 
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therapeuticals like ketotifen for the treatment of ‘Personality Disorders’ (AUC 0.81), and the 
repurposing of antibronchitic drugs to treat ‘Supraventricular Tachycardia’ (AUC 0.81) 
(Figure 5). 
The Drug Side Effect Network 
Finally, linking T and M diseases yields a map that relates treatments to potential adverse 
events. As shown in Table 2, we screened the 835 T chemical—disease pairs to predict 
undesired side effects among the 184 M satisfactory models. The resulting network 
contained as many as 9,921 relationships (Tables 2 and S5). In this network, large 
peripheral nodes are particularly interesting: ‘Seizures’, for instance, has a well-defined 
therapeutic chemistry (AUC 0.71) related to as many as 255 molecules, and is not linked to 
any of the adverse events, suggesting that these treatments are rather safe. When we 
compared our predictions with side effects extracted from drug package labels43, we also 
observed a significant coincidence (8,686 common associations, Ft p-value 6.9·10-21), while 
still providing 1,235 novel predictions. One of them is the possible appearance of ‘Serotonin 
Syndrome’ after exposure to ‘Hyperpituitarism’ (e.g. carmoxirole) and ‘Neointima’ agents like 
nebivolol (AUC of 0.78 and 0.81, respectively) (Figure 5). Nebivolol, in fact, is metabolized 
by CYP450 2D6, resembling serotonin reuptake inhibitors —concomitant treatment with 
such inhibitors may lead to overdose44. Overall, these novel associations contribute to the 
completion of putative drug side effect profiles. In the last years, such profiles have shown 
useful to elucidate molecular events from phenotypic observations45, in turn proving that a lot 
can still be learned from the always imperfect drug molecules46. 
Concluding Remarks 
The current perception is that systems biology will aid the learning of drug action by 
rationalizing the influence that small molecules exert on our health47. In most cases, drug 
action is mediated through receptors, being of critical importance their identification. In a 
previous work48, we reported protein targets shared among drugs with a common effect. Our 
approach was agnostic in the sense that it considered a vast chemical—protein interactome, 
and was therefore suitable to initiate a systems view. Although we recognize the relevance 
of target and off-target identification, we found this knowledge insufficient to anticipate side 
effects, in good agreement with the translational gap in drug discovery49. To complement 
this lack of knowledge, we also mined characteristic chemical moieties inside the drugs with 
the aim to surrogate phenomena that molecular biology is not yet able to consider, as done 
by others50. We learned that chemical structures treasure a remarkable predictive power, 
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although they are difficult to inspect given the small number of known drugs and their sparse 
distribution across the chemical space. Now, our results highlight that collecting and 
grouping molecules with enough insistency aids the modeling of phenotypic implications with 
no need to acknowledge all the underlying biological events. Several studies have proven 
the value of this chemo-centric view of biology. Most notably, such a view allowed for the 
prediction of ligand binding to protein targets with unresolved structures51. Databases like 
ChEMBL52 and BindingDB53, among others, have been essential to decipher relationships 
between chemical features and affinity, and a ligand-centered description of the binding 
event is now feasible4. In these databases, hundreds of thousands of distinct compounds 
are recorded. The ambition to relate chemical structures directly to human-body responses 
is, undoubtedly, a more challenging task, given the complicated intrinsic biology and the lack 
of compound records. We have shown that, even when only a few thousand molecules are 
available, it is already possible to gain some insights. Moreover, we anticipate that the 
number of well-modeled phenotypes could increase considerably in the upcoming years. 
Concretely, we estimate that the amount of accurate classifiers could be doubled if we would 
double the annotation of certain diseases (Figure S8). Approximately, increasing by 25% the 
number of chemical—disease records could result in this doubling of satisfactory models. To 
guide disease annotators, in Table S2 we detail which diseases fall on a learning plateau, be 
it because they are sufficiently apprehended or largely under-annotated, and which cases 
will benefit more from curation efforts54. Likewise, improving disease annotation will enable 
the modeling of more specific phenotyps: terms in this study are slightly broader than those 
commonly used in drug discovery, and these are, in turn, notably unspecific relative to the 
existing medical vocabulary (Figure S9). 
To grow the body of chemical records, improvements in text chemical entity identification55 
and new knowledge discovery concepts56 will be fundamental. Opposite to e.g. genomics, 
large-scale experimentation in chemistry has been conducted primarily by pharmaceutical 
industry and, traditionally, proprietary data have not been available to the community. 
Therefore, scientific literature is still a major support to publish chemical data. We expect 
that, with the advent of text-mining technologies, resources like CTD will continue to expand 
in size and scope. Moreover, current chemical—disease records are being gathered 
together with disease-related genes, which manifests that knowledge is being assembled at 
a fast pace towards a holistic view of biology. Only now, network-based tools to handle such 
complexity are flourishing57, and urgently demand more chemistry awareness58. In this 
context, our study brings chemical cognizance to the systems level, fulfilling a need of 
translational sciences, and widening the applicability of network-based strategies. 
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Materials and Methods 
Chemical Structures 
Compound structures were obtained by querying the Chemical Identifier Resolver 
[cactus.nci.nih.gov] with CTD names. Additionally, we fetched the fraction of chemicals 
contributed by CTD to PubChem [pubchem.ncbi.nlm.nih.gov]. Organometallic compounds 
were excluded and inorganic salts were removed from mixtures. Substances with a 
molecular weight above 800 were also discarded, and stereochemical information was not 
considered. Figure 6 schemes the processing that these molecules underwent. 
Exhaustive Fragmentation 
We exhaustively fragmented each chemical structure through recursive bond breaks down 
to a minimum size of 5 atoms. We followed JChem’s [www.chemaxon.org] CCQ 
fragmentation approach, based on cutting carbon—carbon bonds (CC) if at least one of the 
carbons is bound to a heteroatom (Q). Thus, CCQ rules do not modify functional groups. 
Aliphatic rings and aromatic systems were not cleaved either. The 5% of molecules that 
broke into more than 200 fragments were dismissed. 
Disease Annotation of Chemicals 
We fetched chemical—disease associations from CTD (January 2013)5. This 
knowledgebase includes a controlled vocabulary7 that is based on the ‘Diseases’ branch of 
the National Library of Medicine’s Medical Subject Headers (MeSH). MeSH hierarchy grows 
from broader to more specific disease terms, and molecules are annotated throughout. 
General concepts include annotations from the more specific ones. 
To assign M and T molecules to each disease, we fetched curated (‘Direct evidence’) 
annotations from CTD. Ambiguous annotations (M and T, simultaneously) were removed. 
Molecules labeled in CTD as ‘inferred’ (through gene—disease triangulation59) were also 
discarded since they were confounding the obtainment of disease classifiers (Figure S10). 
The set of ‘unknown’ molecules corresponded to all of those entries that shared no 
relationship (neither curated nor inferred) with none of the terms in the corresponding branch 
of the disease vocabulary. Only diseases annotated with at least 10 molecules entered 
further analysis. In total, we kept 934 M and 835 T chemical-disease relationships. 
Non-redundant Sets of Molecules 
In order to obtain non-redundant sets of chemicals for each disease, we clustered a full pair-
wise chemical similarity matrix. Chemical similarity was measured using topological 
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fingerprints in the RDKit [www.rdkit.org]. The resulting matrix underwent an unsupervised 
clustering with the Butina algorithm60. Clusters were flattened at a Tanimoto cutoff of 0.8, i.e. 
at a distance of 0.2 to the central molecule. Whenever a disease was associated with 
several chemicals in a cluster, the molecule with the highest accumulated similarity to the 
rest was kept as representative for the group. Analogously, we obtained non-redundant sets 
of disease-unrelated chemicals (unknowns).  
Fragment Mining 
Selection of LC Fragments Suitable for Machine Learning 
For each M or T compound—disease pair, we outlined a matrix W listing small molecules in 
the rows and fragments in the columns. To fill in W, we screened each molecule i against all 
of the fragments. A molecule—fragment comparison was performed as follows. First, we 
broke compound i into fragments. The resulting set of fragments was then compared to 
fragment j. The score of this comparison corresponded to the highest Tanimoto similarity of 
MACCS fingerprints, and was kept in cell Wij. MACCS keys are a set of questions about a 
2D structure, and are thus useful to capture chemical features beyond simple topological 
matching. Using MACCS fingerprinting, we increased the power to detect relevant features, 
while diminishing the sparseness of W. 
Then, the width of W was shrunk using statistical filtering. In the resulting matrix WLC, for 
each column j, rows displaying a MACCS similarity > 0.8 were counted, and the significance 
of the over-representation of fragment j among molecules related to the disease was 
assessed using a right-tailed Fisher’s exact test. Please note that the contingency table 
classifies ‘positives’ and ‘unknowns’ (instead of ‘negatives’): this reduces statistical power, 
but should not affect the true positive rate (Figure S11). Those fragments with a p-value < 
0.1 were retained, as recommended in 25. Note that the selection of LC fragments underwent 
a final step that ensured an acceptable tradeoff between classification performance and 
statistical signal (see Data Balancing below). 
Selection of High-Confidence Fragments 
From LC fragments, we selected a subset of HC representatives. In W, these had to elicit an 
odds ratio ≥ 10, a minimum support of 3 molecules and a Benjamini-Hochberg adjusted p-
value < 0.01. To report a diverse and representative set, we grouped those fragments that 
occurred in the same molecules. From each group, the fragment associated with more 
diseases was kept. 
Chemo-centric Disease Models 
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Data Balancing 
In general, few chemicals are known per disease, while the majority of chemicals is not 
related to it. We balanced WLC using a combination of under-sampling and SMOTE over-
sampling61,62. For each case in the minority class (i.e. chemicals annotated with a disease of 
interest), 5 new examples were created, up to a maximum of 1,000 instances. The majority 
class (i.e. ‘unknown’ cases) was under-sampled to achieve a 1:1 proportion with the minority 
class. 
Then, columns in the balanced dataset (WLC’) were hierarchically clustered using 
Fastcluster63, and branches were pruned using DynamicTreeCut64 with a minimum cluster 
size of 1. Inside each cluster, fragments were compared all-against-all to detect parent—
child relationships. For a lineage of fragments, the one with the best initial over-
representation p-value was retained. Overall, this led to matrices WLC’’ that had an even 
sampling through the rows and a simplified set of LC over-represented fragments in the 
columns. 
Chemical Classifiers 
WLC’’ matrices above are suitable for machine learning because they have a balanced class 
distribution, and a representative and reasonably distinct set of variables. Given its general 
robustness in the learning of structure-activity relationships65, we chose to build chemical 
classifiers with the random forest algorithm. For this, we used the randomForest R-
package66, growing 10,000 trees and taking default values for the rest of parameters. Since 
each tree returns a decision, class probabilities were estimated from voting. 
Cross-validation 
As schemed in Figure 6, we performed a stratified 10-fold cross-validation of predictive 
models. Test and training sets were split before the LC fragment mining step (i.e. before the 
variable selection, and therefore previous to the data balancing). Performance metrics in 
Table 1 were obtained from the reassembled vector of test predictions. 
Disease Networks 
Network Construction 
In a chemo-centric disease network, disease A is linked to disease B if molecules annotated 
to A are predicted to relate with B. Since we obtained M and T models, we can propose, at 
least, three different networks (Figure 5A and Table 2): (1) a comorbidity network, that links 
A to B if chemicals that cause A are predicted to cause B; (2) a drug repositioning network, 
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where chemicals employed to treat A may also be useful to treat B; and (3) a drug side 
effect network, that relates A to B when chemicals used in the treatment of A could cause B. 
To infer an edge from A to B, we tested A curated chemicals together with a set of chemicals 
unrelated to A and B using the B random forest classifier. The strength of the association 
was assessed with the AUC of the cross-classification ROC plot, where molecules predicted 
to associate with B are checked for their association with A. Note that we removed easy 
cases by discarding disease pairs in the same branch of the medical hierarchy. To mine the 
examples discussed in Figure 5, we only considered those pairs that shared no chemicals, 
highlighting the importance of the fragment mining procedure. 
Network Analysis 
Comparison of the Comorbidity Network with a Clinical Disease Co-occurrence Network 
A clinical disease network was obtained from Hudine38, a comorbidity network that reports 
the relative risk (RR) of experiencing a disease when another disease is diagnosed. In 
Hudine, clinical reports are stored using the International Classification of Diseases, 9th 
revision (ICD-9). The mapping between MeSH and ICD-9 (3-digits code) terms was 
achieved using BioPortal’s [bioportal.bioontology.org] UMLS concepts, and by best-matching 
MeSH and ICD-9 UMLS concepts with the UMLS-similarity Perl-package67 (vector 
relatedness > 0.8). We assigned a significance p-value to the coincidence between our 
chemo-centric network and Hudine comorbidities (RR ≥ 20 or ϕ ≥ 0.06, as in 38) by using a 
right-tailed Fisher’s exact test. The corresponding confusion matrix classified predicted and 
unpredicted pairs, and pairs that were mapped and not mapped to Hudine. 
In order to demonstrate the need for robust disease models, we also built a comorbidity 
network (same [A] and [B] sets) that linked A to B simply if at least 50% of A LC fragments 
were LC fragments of B. In addition to a reduction in the number of edges of two orders of 
magnitude, we observed no significant coincidence with the clinical network. 
Comparison of the Drug Repositioning Network with a Drug Repositioning Network Derived 
from Known Drugs 
Disease—disease associations were inferred based on drug indications42. Similar to 68, for a 
pair of diseases A and B, we filled a 2x2 confusion matrix counting the number of drugs that 
are used to treat both, one or none of the diseases. From this matrix, we obtained the two-
tailed p-value of a Fisher’s test and the Matthews correlation coefficient (MCC). A and B 
were linked in the drug repositioning network if p-value ≤ 0.05 and MCC ≥ 0.1568. Like 
above, node mapping was achieved using UMLS term similarities, and the significance of 
  18 
the overlap with our results was evaluated analogously. Here again, we checked that the 
modeling step was important to provide significant results. 
Comparison of the Side Effect Network with Side Effects Reported in Drug Labels 
We collected a side effect network from 68. This network represents side effects that occur 
frequently among approved drugs prescribed for a particular disease. As done for the 
comorbidity and the drug repositioning networks, we analyzed its coincidence with our 
chemo-centric map, and confirmed the convenience of disease models for building the 
network. 
Acknowledgements 
We thank Evarist Planet and Samira Jaeger (IRB) for helpful discussions. This work was 
partially supported by the Spanish Ministerio de Ciencia e Innovación (BIO2010-22073), the 
European Commission under FP7 Grant Agreement 306240 (SyStemAge) and the 
European Research Council through the SysPharmAD grant (Agreement no: 201014). MD-F 
is a recipient of the Spanish FPU fellowship. 
Author contributions 
MD-F, DR and PA designed the study and wrote the manuscript. MD-F performed the 
experiments and analyzed the results. 
 
Competing Financial Interests statement 
 
The authors declare no competing financial interests. 
  
  19 
References 
1 Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L. & Vidal, M. Drug-target network. 
Nature biotechnology 25, 1119-1126, doi:10.1038/nbt1338 (2007). 
2 Bauer-Mehren, A. et al. Automatic filtering and substantiation of drug safety signals. PLoS 
computational biology 8, e1002457, doi:10.1371/journal.pcbi.1002457 (2012). 
3 Pujol, A., Mosca, R., Farres, J. & Aloy, P. Unveiling the role of network and systems biology 
in drug discovery. Trends in pharmacological sciences 31, 115-123, 
doi:10.1016/j.tips.2009.11.006 (2010). 
4 Keiser, M. J., Irwin, J. J. & Shoichet, B. K. The chemical basis of pharmacology. Biochemistry 
49, 10267-10276, doi:10.1021/bi101540g (2010). 
5 Davis, A. P. et al. The Comparative Toxicogenomics Database: update 2013. Nucleic acids 
research 41, D1104-1114, doi:10.1093/nar/gks994 (2013). 
6 Wishart, D. S. Chapter 3: Small molecules and disease. PLoS computational biology 8, 
e1002805, doi:10.1371/journal.pcbi.1002805 (2012). 
7 Davis, A. P., Wiegers, T. C., Rosenstein, M. C. & Mattingly, C. J. MEDIC: a practical disease 
vocabulary used at the Comparative Toxicogenomics Database. Database : the journal of 
biological databases and curation 2012, bar065, doi:10.1093/database/bar065 (2012). 
8 Varin, T., Schuffenhauer, A., Ertl, P. & Renner, S. Mining for bioactive scaffolds with scaffold 
networks: improved compound set enrichment from primary screening data. Journal of 
chemical information and modeling 51, 1528-1538, doi:10.1021/ci2000924 (2011). 
9 Wetzel, S. et al. Interactive exploration of chemical space with Scaffold Hunter. Nature 
chemical biology 5, 581-583, doi:10.1038/nchembio.187 (2009). 
10 Shultz, M. D. Setting expectations in molecular optimizations: strengths and limitations of 
commonly used composite parameters. Bioorganic & Medicinal Chemistry Letters 231, 5980–
5991, doi:http://dx.doi.org/10.1016/j.bmcl.2013.08.029 (2013). 
11 Congreve, M., Carr, R., Murray, C. & Jhoti, H. A 'rule of three' for fragment-based lead 
discovery? Drug discovery today 8, 876-877 (2003). 
12 Langdon, S. R., Brown, N. & Blagg, J. Scaffold diversity of exemplified medicinal chemistry 
space. Journal of chemical information and modeling 51, 2174-2185, doi:10.1021/ci2001428 
(2011). 
13 Akritopoulou-Zanze, I. & Hajduk, P. J. Kinase-targeted libraries: the design and synthesis of 
novel, potent, and selective kinase inhibitors. Drug discovery today 14, 291-297, 
doi:10.1016/j.drudis.2008.12.002 (2009). 
14 Lameijer, E. W., Kok, J. N., Back, T. & Ijzerman, A. P. Mining a chemical database for 
fragment co-occurrence: discovery of "chemical cliches". Journal of chemical information and 
modeling 46, 553-562, doi:10.1021/ci050370c (2006). 
15 Bemis, G. W. & Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. 
Journal of medicinal chemistry 39, 2887-2893, doi:10.1021/jm9602928 (1996). 
16 Lipkus, A. H. et al. Structural diversity of organic chemistry. A scaffold analysis of the CAS 
Registry. The Journal of organic chemistry 73, 4443-4451, doi:10.1021/jo8001276 (2008). 
  20 
17 Pitt, W. R., Parry, D. M., Perry, B. G. & Groom, C. R. Heteroaromatic rings of the future. 
Journal of medicinal chemistry 52, 2952-2963, doi:10.1021/jm801513z (2009). 
18 Williams, D. P. Toxicophores: investigations in drug safety. Toxicology 226, 1-11, 
doi:10.1016/j.tox.2006.05.101 (2006). 
19 Welsch, M. E., Snyder, S. A. & Stockwell, B. R. Privileged scaffolds for library design and 
drug discovery. Current opinion in chemical biology 14, 347-361, 
doi:10.1016/j.cbpa.2010.02.018 (2010). 
20 Wester, M. J. et al. Scaffold topologies. 2. Analysis of chemical databases. Journal of 
chemical information and modeling 48, 1311-1324, doi:10.1021/ci700342h (2008). 
21 Knox, C. et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. 
Nucleic acids research 39, D1035-1041, doi:10.1093/nar/gkq1126 (2011). 
22 Dupont, E., Mikkelsen, B. & Jakobsen, J. Mesulergine in early Parkinson's disease: a double 
blind controlled trial. Journal of neurology, neurosurgery, and psychiatry 49, 390-395 (1986). 
23 Mavridis, L., Hudson, B. D. & Ritchie, D. W. Toward high throughput 3D virtual screening 
using spherical harmonic surface representations. Journal of chemical information and 
modeling 47, 1787-1796, doi:10.1021/ci7001507 (2007). 
24 Takigawa, I. & Mamitsuka, H. Graph mining: procedure, application to drug discovery and 
recent advances. Drug discovery today 18, 50-57, doi:10.1016/j.drudis.2012.07.016 (2013). 
25 Wang, Y. et al. Estimation of carcinogenicity using molecular fragments tree. Journal of 
chemical information and modeling 52, 1994-2003, doi:10.1021/ci300266p (2012). 
26 Greene, N., Judson, P. N., Langowski, J. J. & Marchant, C. A. Knowledge-based expert 
systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR and QSAR 
in environmental research 10, 299-314, doi:10.1080/10629369908039182 (1999). 
27 Berger, S. I., Ma'ayan, A. & Iyengar, R. Systems pharmacology of arrhythmias. Science 
signaling 3, ra30, doi:10.1126/scisignal.2000723 (2010). 
28 Nakajima, A. et al. Investigation of glucocorticoid-induced side effects in patients with 
autoimmune diseases. Journal of the Pharmaceutical Society of Japan 129, 445-450 (2009). 
29 Yang, P., Li, X. L., Mei, J. P., Kwoh, C. K. & Ng, S. K. Positive-unlabeled learning for disease 
gene identification. Bioinformatics 28, 2640-2647, doi:10.1093/bioinformatics/bts504 (2012). 
30 Zhang, B. & Zuo, W. Reliable negative extracting based on kNN for learning from positive and 
unlabeled examples. Journal of Computers 4, 94-101 (2009). 
31 Liu, B., Lee, W. S., Yu, P. & Li, X. Partially supervised classification of text documents ICML-
02 (2002). 
32 Davis, A. P. et al. A CTD-Pfizer collaboration: manual curation of 88,000 scientific articles text 
mined for drug-disease and drug-phenotype interactions. Database : the journal of biological 
databases and curation 2013, bat080, doi:10.1093/database/bat080 (2013). 
33 Liew, C. Y., Pan, C., Tan, A., Ang, K. X. & Yap, C. W. QSAR classification of metabolic 
activation of chemicals into covalently reactive species. Molecular diversity 16, 389-400, 
doi:10.1007/s11030-012-9364-3 (2012). 
  21 
34 Casalegno, M. & Sello, G. Determination of toxicant mode of action by augmented top priority 
fragment class. Journal of chemical information and modeling 53, 1113-1126, 
doi:10.1021/ci400130n (2013). 
35 Barabasi, A. L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to 
human disease. Nature reviews. Genetics 12, 56-68, doi:10.1038/nrg2918 (2011). 
36 Jacunski, A. & Tatonetti, N. Connecting the Dots: Applications of Network Medicine in 
Pharmacology and Disease. Clinical pharmacology and therapeutics, 
doi:10.1038/clpt.2013.168 (2013). 
37 Goh, K. I. et al. The human disease network. Proceedings of the National Academy of 
Sciences of the United States of America 104, 8685-8690, doi:10.1073/pnas.0701361104 
(2007). 
38 Hidalgo, C. A., Blumm, N., Barabasi, A. L. & Christakis, N. A. A dynamic network approach 
for the study of human phenotypes. PLoS computational biology 5, e1000353, 
doi:10.1371/journal.pcbi.1000353 (2009). 
39 Lee, D. S. et al. The implications of human metabolic network topology for disease 
comorbidity. Proceedings of the National Academy of Sciences of the United States of 
America 105, 9880-9885, doi:10.1073/pnas.0802208105 (2008). 
40 Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for 
existing drugs. Nature reviews. Drug discovery 3, 673-683, doi:10.1038/nrd1468 (2004). 
41 Chiang, A. P. & Butte, A. J. Systematic evaluation of drug-disease relationships to identify 
leads for novel drug uses. Clinical pharmacology and therapeutics 86, 507-510, 
doi:10.1038/clpt.2009.103 (2009). 
42 Gottlieb, A., Stein, G. Y., Ruppin, E. & Sharan, R. PREDICT: a method for inferring novel 
drug indications with application to personalized medicine. Molecular systems biology 7, 496, 
doi:10.1038/msb.2011.26 (2011). 
43 Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J. & Bork, P. A side effect resource to capture 
phenotypic effects of drugs. Molecular systems biology 6, 343, doi:10.1038/msb.2009.98 
(2010). 
44 Gielen, W., Cleophas, T. J. & Agrawal, R. Nebivolol: a review of its clinical and 
pharmacological characteristics. International journal of clinical pharmacology and 
therapeutics 44, 344-357 (2006). 
45 Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J. & Bork, P. Drug target identification using 
side-effect similarity. Science 321, 263-266, doi:10.1126/science.1158140 (2008). 
46 Duran-Frigola, M. & Aloy, P. Recycling side-effects into clinical markers for drug repositioning. 
Genome medicine 4, 3, doi:10.1186/gm302 (2012). 
47 Russell, R. B. & Aloy, P. Targeting and tinkering with interaction networks. Nature chemical 
biology 4, 666-673, doi:10.1038/nchembio.119 (2008). 
48 Duran-Frigola, M. & Aloy, P. Analysis of chemical and biological features yields mechanistic 
insights into drug side effects. Chemistry & biology 20, 594-603, 
doi:10.1016/j.chembiol.2013.03.017 (2013). 
49 Pammolli, F., Magazzini, L. & Riccaboni, M. The productivity crisis in pharmaceutical R&D. 
Nature reviews. Drug discovery 10, 428-438, doi:10.1038/nrd3405 (2011). 
  22 
50 Audouze, K. et al. Deciphering diseases and biological targets for environmental chemicals 
using toxicogenomics networks. PLoS computational biology 6, e1000788, 
doi:10.1371/journal.pcbi.1000788 (2010). 
51 Keiser, M. J. et al. Relating protein pharmacology by ligand chemistry. Nature biotechnology 
25, 197-206, doi:10.1038/nbt1284 (2007). 
52 Bellis, L. J. et al. Collation and data-mining of literature bioactivity data for drug discovery. 
Biochemical Society transactions 39, 1365-1370, doi:10.1042/BST0391365 (2011). 
53 Liu, T., Lin, Y., Wen, X., Jorissen, R. N. & Gilson, M. K. BindingDB: a web-accessible 
database of experimentally determined protein-ligand binding affinities. Nucleic acids 
research 35, D198-201, doi:10.1093/nar/gkl999 (2007). 
54 Davis, A. P. et al. Text mining effectively scores and ranks the literature for improving 
chemical-gene-disease curation at the comparative toxicogenomics database. PloS one 8, 
e58201, doi:10.1371/journal.pone.0058201 (2013). 
55 Grego, T. & Couto, F. M. Enhancement of chemical entity identification in text using semantic 
similarity validation. PloS one 8, e62984, doi:10.1371/journal.pone.0062984 (2013). 
56 Ding, Y. et al. Entitymetrics: measuring the impact of entities. PloS one 8, e71416, 
doi:10.1371/journal.pone.0071416 (2013). 
57 Hu, Z. et al. VisANT 4.0: Integrative network platform to connect genes, drugs, diseases and 
therapies. Nucleic acids research 41, W225-231, doi:10.1093/nar/gkt401 (2013). 
58 Oprea, T. I., May, E. E., Leitao, A. & Tropsha, A. Computational systems chemical biology. 
Methods Mol Biol 672, 459-488, doi:10.1007/978-1-60761-839-3_18 (2011). 
59 King, B. L., Davis, A. P., Rosenstein, M. C., Wiegers, T. C. & Mattingly, C. J. Ranking 
transitive chemical-disease inferences using local network topology in the comparative 
toxicogenomics database. PloS one 7, e46524, doi:10.1371/journal.pone.0046524 (2012). 
60 Butina, D. Unsupervised Data Base Clustering Based on Daylight's Fingerprint and Tanimoto 
Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets. Journal of 
Chemical Information and Computer Sciences 39, 747-750, doi:10.1021/ci9803381 (1999). 
61 Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. Smote: Synthetic minority 
over-sampling technique. Journal of Artificial Intelligence Research 16, 321-357 (2002). 
62 Torgo, L. Data Mining with R, learning with case studies.  (Chapman and Hall/CRC, 2010). 
63 Müllner, D. Fastcluster: Fast Hierarchical, Agglomerative Clustering Routines for R and 
Python. Journal of Statistical Software 53, 18 (2013). 
64 Langfelder, P., Zhang, B. & Horvath, S. Defining clusters from a hierarchical cluster tree: the 
Dynamic Tree Cut package for R. Bioinformatics 24, 719-720, 
doi:10.1093/bioinformatics/btm563 (2008). 
65 Wildenhain, J., Fitzgerald, N. & Tyers, M. MolClass: a web portal to interrogate diverse small 
molecule screen datasets with different computational models. Bioinformatics 28, 2200-2201, 
doi:10.1093/bioinformatics/bts349 (2012). 
66 Liaw, A. & Wiener, M. Classification and Regression by randomForest. R News 2, 18-22 
(2002). 
  23 
67 McInnes, B. T., Pedersen, T. & Pakhomov, S. V. UMLS-Interface and UMLS-Similarity : open 
source software for measuring paths and semantic similarity. AMIA ... Annual Symposium 
proceedings / AMIA Symposium. AMIA Symposium 2009, 431-435 (2009). 
68 Yang, L. & Agarwal, P. Systematic drug repositioning based on clinical side-effects. PloS one 
6, e28025, doi:10.1371/journal.pone.0028025 (2011). 
 
  24 
Figure and Table Legends 
Figure 1. Over-represented fragments. (A) Fragments per disease (left) and diseases per 
fragment (right), considering only the HC set. In the middle, a Voronoi diagram where each 
fragment is a shape with area and color proportional to the number of molecules that contain 
it (best match similarity > 0.8). (B) Chemical diversity. We display the cumulative distribution 
of the total number of atoms (left), the number of heteroatoms (middle), and the number of 
rings (right). Distributions are decorated with illustrative fragment structures. M and T 
chemical-disease relationships are shown in orange and green colors, respectively. 
Figure 2. Privileged and liable structures. (A) Balance between privileged and liable 
structures, both for the HC and LC sets. % of M indicates the proportion of M associations 
for each fragment over its disease associations. (B) On the right, three scaffolds that, while 
being mostly liable, are included in drug molecules. On the left, fragments that are privileged 
and remain unsuccessful or unexplored as therapeutics. Next to each structure, top and 
bottom pie charts represent the number of diseases for which the fragment is LC- and HC-
associated, respectively. Area of pie charts is proportional to the number of diseases. To 
select these examples, experimental and approved drug structures were extracted from 
Drugbank (July 2013) 21, and treated like CTD compounds. 
Figure 3. Predictive models. In the middle, AUC distribution of M and T models. Area 
under a density region is proportional to the number of diseases. On the left and right 
panels, example ROC plots for M and T chemical-disease relationships, respectively. 
Figure 4. Disease categories of successful models. M and T plausible disease models 
classified into high-level disease categories. Each circle represents an M or T disease model 
belonging to the corresponding category. Area of circles is proportional to the number of 
associated molecules in our dataset. 
Figure 5. Disease networks. Disease comorbidity, drug repositioning and drug side effect 
networks. Examples discussed in the text are depicted with directed links on top of each 
network. To select these examples, we looked for strong correlations (see Materials and 
Methods) occurring between diseases in different categories. None of the cases share 
annotated chemicals, highlighting the value of our fragment-based models. Networks are 
displayed with a gravity layout, being node size proportional to the number of related 
chemicals. Network statistics can be found in Table 2. 
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Figure 6. Scheme of the method. Analysis protocol exemplified for an M disease of 
interest. (1) Annotated molecules are collected and split in training and test sets. (2) M 
training molecules are fragmented using CCQ rules. (3) W is built from the resulting 
fragments (columns) and the training set (rows) (stratified 10-fold cross-validation). W 
undergoes a significance filtering, a data balancing step, a column clustering and a pruning, 
resulting in WLC’. (4) Columns of WLC’ constitute the LC set of fragments; (5) further filtering 
considering substructural relationships and co-occurrence in molecules yields the HC set. 
(6) Using WLC’, a random forest classifier is learned, and (7) tested against the test set. If the 
model performs with AUC > 0.7, it is considered of good quality. (8) Steps 1-7 are conducted 
for all M and T chemical-disease relationships. (9) Using plausible models, chemo-centric 
disease networks are constructed. 
Table 1. Disease and fragment statistics 
Analysis of M and T chemical-disease annotations, ‘Total’ column refers to the union of both 
categories. When applicable, median values are shown for count data, while mean values 
are shown for performance metrics. Point performance metrics are taken with default 0.5 
cutoff in the random forest classifier. The cutoff could be slid along the classifier’s outcome 
to get different point performances along the ROC space. 
Table 2. Network statistics 
General statistics of the chemo-centric disease networks. 
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Table 1. 
 M T Total 
Diseases 934 835 1,176 
Molecules per disease 36 25 30 
LC fragments 23,135 28,325 37,809 
HC fragments 910 1,107 1,550 
LC fragments per disease 204.5 196.5 200.5 
HC fragments per disease 5 6 6 
Liable (M) and privileged (T) fragments 348 367 715 
Diseases with ≥ 1 HC fragment 385 409 794 
AUC 0.613 0.641 0.627 
Specificity 0.878 0.882 0.880 
Sensitivity 0.265 0.292 0.278 
Balanced accuracy 0.571 0.588 0.579 
Positive predictive value 0.032 0.023 0.029 
G-mean 0.463 0.488 0.475 
F1-score 0.053 0.044 0.049 
Diseases with AUC > 0.7 184 216 400 
 
Table 2. 
 Target 
Diseases 
Source 
Diseases 
Nodes Directed 
Edges 
In-
degree 
Out-
degree 
Undirected 
edges 
Degree 
Comorbidity 184 M 934 M 934 12,610 44.5 7 10,917 8 
Repositioning 216 T  835 T 835 14,590 63 7 11,997 8 
Side effect 184 M 835 T 1,019 9,921 31.5 2 9,921 8 
 
 
